Small molecule therapeutics for autoimmune & inflammatory diseases and cancer
Rigel (NASDAQ: RIGL) is focused on discovery and development of therapeutics against novel targets implicated in autoimmune diseases, inflammatory diseases, and cancer. Rigel completed its IPO in 2000.